GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Research & Development

BerGenBio ASA (OSL:BGBIO) Research & Development : kr93.04 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BerGenBio ASA's Research & Development for the three months ended in Jun. 2024 was kr32.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was kr93.04 Mil.

BerGenBio ASA Research & Development Historical Data

The historical data trend for BerGenBio ASA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Research & Development Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only 162.86 185.23 205.82 202.40 107.79

BerGenBio ASA Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.16 9.77 29.36 21.89 32.03

BerGenBio ASA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr93.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BerGenBio ASA  (OSL:BGBIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BerGenBio ASA Research & Development Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

BerGenBio ASA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Research & Development
Comparable Companies
OSL:CIRCA OSL:EXTX OSL:TRMED OSL:LYTIX OSL:ABS OSL:PCIB OSL:ABTEC OSL:SOFTX OSL:CRNA OSL:HBC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0RU5:UK 7BG0:Germany
Address
Mollendalsbakken 9, Bergen, NOR, 5009
Website
https://www.bergenbio.com
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA Headlines

No Headlines